Hembrough, Todd,Cecchi, Fabiola,Schwartz, Sarit,Yau, Christina
申请号：
AU2018275156
公开号：
AU2018275156A1
申请日:
2018.06.04
申请国别(地区):
AU
年份:
2019
代理人:
摘要：
Methods are provided for identifying whether a cancer patient, and especially a gastric cancer patient, will be responsive to treatment with a sequential therapeutic strategy comprising a first administration of the FOLFIRI regimen (irinotecan/5-fluoruracil/folinic acid) followed by a separate sequential administration of the combination of the chemotherapy agents docetaxel and cisplatin (FOLFIRI + docetaxel/cisplatin). Specified TUBB3 and TYMP fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, and especially gastric cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the sequential combination treatment of FOLFIRI + docetaxel/cisplatin.
